Network Approaches for Modeling the Effect of Drugs and Diseases

Overview

Journal Brief Bioinform

Publisher Oxford University Press

Specialty Biology

Date 2022 Jun 15

PMID 35704883

Authors

T J Rintala

Arindam Ghosh

V Fortino

Affiliations

Soon will be listed here.

Abstract

The network approach is quickly becoming a fundamental building block of computational methods aiming at elucidating the mechanism of action (MoA) and therapeutic effect of drugs. By modeling the effect of drugs and diseases on different biological networks, it is possible to better explain the interplay between disease perturbations and drug targets as well as how drug compounds induce favorable biological responses and/or adverse effects. Omics technologies have been extensively used to generate the data needed to study the mechanisms of action of drugs and diseases. These data are often exploited to define condition-specific networks and to study whether drugs can reverse disease perturbations. In this review, we describe network data mining algorithms that are commonly used to study drug's MoA and to improve our understanding of the basis of chronic diseases. These methods can support fundamental stages of the drug development process, including the identification of putative drug targets, the in silico screening of drug compounds and drug combinations for the treatment of diseases. We also discuss recent studies using biological and omics-driven networks to search for possible repurposed FDA-approved drug treatments for SARS-CoV-2 infections (COVID-19).

Citing Articles

Untargeted metabolome atlas for sleep-related phenotypes in the Hispanic community health study/study of Latinos.

Zhang Y, Spitzer B, Zhang Y, Wallace D, Yu B, Qi Q EBioMedicine. 2024; 111():105507.

PMID: 39693737 PMC: 11722176. DOI: 10.1016/j.ebiom.2024.105507.

Untargeted Metabolome Atlas for Sleep Phenotypes in the Hispanic Community Health Study/Study of Latinos.

Zhang Y, Spitzer B, Zhang Y, Wallace D, Yu B, Qi Q medRxiv. 2024; .

PMID: 38798578 PMC: 11118618. DOI: 10.1101/2024.05.17.24307286.

Optimal fusion of genotype and drug embeddings in predicting cancer drug response.

Nguyen T, Campbell A, Kumar A, Amponsah E, Fiterau M, Shahriyari L Brief Bioinform. 2024; 25(3).

PMID: 38754407 PMC: 11097979. DOI: 10.1093/bib/bbae227.

Computational model for drug research.

Chen X, Huang L Brief Bioinform. 2024; 25(3).

PMID: 38581423 PMC: 10998638. DOI: 10.1093/bib/bbae158.

Network-based cytokine inference implicates Oncostatin M as a driver of an inflammation phenotype in knee osteoarthritis.

Iijima H, Zhang F, Ambrosio F, Matsui Y Aging Cell. 2023; 23(2):e14043.

PMID: 38111237 PMC: 10861212. DOI: 10.1111/acel.14043.

References

Cai M, Xu Q, Pan Y, Pan W, Ji N, Li Y . ADReCS: an ontology database for aiding standardization and hierarchical classification of adverse drug reaction terms. Nucleic Acids Res. 2014; 43(Database issue):D907-13. PMC: 4383906. DOI: 10.1093/nar/gku1066. View

Zhang W, Yue X, Lin W, Wu W, Liu R, Huang F . Predicting drug-disease associations by using similarity constrained matrix factorization. BMC Bioinformatics. 2018; 19(1):233. PMC: 6006580. DOI: 10.1186/s12859-018-2220-4. View

Forster P, Forster L, Renfrew C, Forster M . Phylogenetic network analysis of SARS-CoV-2 genomes. Proc Natl Acad Sci U S A. 2020; 117(17):9241-9243. PMC: 7196762. DOI: 10.1073/pnas.2004999117. View

van Driel M, Bruggeman J, Vriend G, Brunner H, Leunissen J . A text-mining analysis of the human phenome. Eur J Hum Genet. 2006; 14(5):535-42. DOI: 10.1038/sj.ejhg.5201585. View

Sun M, Zhao S, Gilvary C, Elemento O, Zhou J, Wang F . Graph convolutional networks for computational drug development and discovery. Brief Bioinform. 2019; 21(3):919-935. DOI: 10.1093/bib/bbz042. View

Nelson C, Butte A, Baranzini S . Integrating biomedical research and electronic health records to create knowledge-based biologically meaningful machine-readable embeddings. Nat Commun. 2019; 10(1):3045. PMC: 6620318. DOI: 10.1038/s41467-019-11069-0. View

Martinez V, Navarro C, Cano C, Fajardo W, Blanco A . DrugNet: network-based drug-disease prioritization by integrating heterogeneous data. Artif Intell Med. 2015; 63(1):41-9. DOI: 10.1016/j.artmed.2014.11.003. View

Szklarczyk D, Santos A, von Mering C, Jensen L, Bork P, Kuhn M . STITCH 5: augmenting protein-chemical interaction networks with tissue and affinity data. Nucleic Acids Res. 2015; 44(D1):D380-4. PMC: 4702904. DOI: 10.1093/nar/gkv1277. View

Huang Z, Shi J, Gao Y, Cui C, Zhang S, Li J . HMDD v3.0: a database for experimentally supported human microRNA-disease associations. Nucleic Acids Res. 2018; 47(D1):D1013-D1017. PMC: 6323994. DOI: 10.1093/nar/gky1010. View

10.

Serra A, Fratello M, Fortino V, Raiconi G, Tagliaferri R, Greco D . MVDA: a multi-view genomic data integration methodology. BMC Bioinformatics. 2015; 16:261. PMC: 4539887. DOI: 10.1186/s12859-015-0680-3. View

11.

Igarashi Y, Nakatsu N, Yamashita T, Ono A, Ohno Y, Urushidani T . Open TG-GATEs: a large-scale toxicogenomics database. Nucleic Acids Res. 2014; 43(Database issue):D921-7. PMC: 4384023. DOI: 10.1093/nar/gku955. View

12.

Raghavan U, Albert R, Kumara S . Near linear time algorithm to detect community structures in large-scale networks. Phys Rev E Stat Nonlin Soft Matter Phys. 2007; 76(3 Pt 2):036106. DOI: 10.1103/PhysRevE.76.036106. View

13.

Jiang H, Huang Y, You Z . SAEROF: an ensemble approach for large-scale drug-disease association prediction by incorporating rotation forest and sparse autoencoder deep neural network. Sci Rep. 2020; 10(1):4972. PMC: 7080766. DOI: 10.1038/s41598-020-61616-9. View

14.

Tate J, Bamford S, Jubb H, Sondka Z, Beare D, Bindal N . COSMIC: the Catalogue Of Somatic Mutations In Cancer. Nucleic Acids Res. 2018; 47(D1):D941-D947. PMC: 6323903. DOI: 10.1093/nar/gky1015. View

15.

Mounika Inavolu S, Renbarger J, Radovich M, Vasudevaraja V, Kinnebrew G, Zhang S . IODNE: An integrated optimization method for identifying the deregulated subnetwork for precision medicine in cancer. CPT Pharmacometrics Syst Pharmacol. 2017; 6(3):168-176. PMC: 5351413. DOI: 10.1002/psp4.12167. View

16.

Cheng F, Desai R, Handy D, Wang R, Schneeweiss S, Barabasi A . Network-based approach to prediction and population-based validation of in silico drug repurposing. Nat Commun. 2018; 9(1):2691. PMC: 6043492. DOI: 10.1038/s41467-018-05116-5. View

17.

Jin S, Niu Z, Jiang C, Huang W, Xia F, Jin X . HeTDR: Drug repositioning based on heterogeneous networks and text mining. Patterns (N Y). 2021; 2(8):100307. PMC: 8369234. DOI: 10.1016/j.patter.2021.100307. View

18.

Pouryahya M, Oh J, Mathews J, Belkhatir Z, Moosmuller C, Deasy J . Pan-Cancer Prediction of Cell-Line Drug Sensitivity Using Network-Based Methods. Int J Mol Sci. 2022; 23(3). PMC: 8835038. DOI: 10.3390/ijms23031074. View

19.

Kanehisa M, Sato Y, Kawashima M . KEGG mapping tools for uncovering hidden features in biological data. Protein Sci. 2021; 31(1):47-53. PMC: 8740838. DOI: 10.1002/pro.4172. View

20.

Cheng F, Kovacs I, Barabasi A . Network-based prediction of drug combinations. Nat Commun. 2019; 10(1):1197. PMC: 6416394. DOI: 10.1038/s41467-019-09186-x. View